Fundraising Fox
🦊/Companies
Sign in

YolTech Therapeutics

2 known investors

Find your way into YolTech Therapeutics

YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

DY
Dr. Yuxuan WuCo-founder & CEO

Investors · 2

Decheng CapitalMenlo Park

Also in the syndicate · 1

AstraZeneca-CICClead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries BSep 2025

    AstraZeneca-CICC (lead)

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 202612 Funding Rounds That Show Where APAC Biotech Capital Is Goingbiopharmaapac.com · Jul 2026YolTech Raises $70M to Advance Expanding In Vivo Gene Editing Pipeline | PackGene Biotechpackgene.com · May 2026YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICCprnewswire.com · Sep 2025Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 studyendpoints.news · Sep 2025YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)prnewswire.com · Jun 2025

Frequently asked questions

What does YolTech Therapeutics do?
YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.
Who founded YolTech Therapeutics?
YolTech Therapeutics was founded by Dr. Yuxuan Wu.
Who are YolTech Therapeutics's investors?
YolTech Therapeutics's investors include Decheng Capital.